Protagenic Therapeutics Inc - Warrants (13/04/2025)
PTIXW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.45M
Close$
$0.38
2401.3% upside
Current Fair Value
2401.3% upsideUndervalued by 2401.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.45 Million |
|---|---|
| Enterprise Value | $883,992.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.45 |
| Beta | 0.47 |
| Outstanding Shares | 1,810,208 |
Return
| Return on Equity | 316.93% |
|---|---|
| Return on Assets | 261.82% |
| Return on Invested Capital | -420.80% |
Valuation & Multiples
| P/E Ratio | 0.27 |
|---|---|
| PEG | -0.34 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.50%▼ 0.32% |
|---|---|
| Total Invested | $5,468▲ 6.80% |
| Investors Holding | 3▼ 1.00% |
ESG Score
No data
About Protagenic Therapeutics Inc
1 employeesProtagenic Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorder...